Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;66(3):152-156.
doi: 10.1111/ajd.14427. Epub 2025 Feb 5.

Biosimilars for Australian Dermatologists

Grace X Li  1   2 , Mona Marabani  3 , Deshan F Sebaratnam  1   2
Affiliations

Biosimilars for Australian Dermatologists

Grace X Li et al. Australas J Dermatol. 2025 May.

Abstract

Biosimilars offer the potential for substantial cost savings within the Australian healthcare system. This is particularly salient in dermatology, where biologics are used to treat chronic skin diseases and cost savings will be accrued throughout the life of a patient. However, uptake of biosimilars in clinical practice has been hindered by barriers including insufficient clinician education, concerns about safety and efficacy, and negative patient perception. Increased availability of biosimilars promotes long-term sustainability of the Pharmaceutical Benefits Scheme and may help maintain equitable access to healthcare across Australia.

Keywords: biologic; biological agent; biosimilar; dermatology; economic; sustainability.

PubMed Disclaimer

Conflict of interest statement

D.F.S. has received consulting fees from Galderma, AbbVie, Pfizer, Amgen, Novartis, Janssen, Leo Pharma, Bristol Myers Squibb, Eli Lilly, iNOVA, Ego Pharmaceuticals, and Sun Pharma, and material support from Candela Medical and Heine Optotechnik. D.F.S. is an Editorial Board member of Australasian Journal of Dermatology and a co‐author of this article. To minimise bias, he was excluded from all editorial decision‐making related to the acceptance of this article for publication. M.M. has received consulting fees from Abbvie, Eli Lilly, Amgen, UCB and conference support from Pfizer and Novartis. G.X.L. has no conflicts of interest to report.

References

    1. Department of Health and Aged Care , “Pharmaceutical Benefits Scheme—Biosimilar Rituximab,” 2022, https://www.health.gov.au/sites/default/files/documents/2022/09/biosimil....
    1. Gleeson D., Townsend B., Lopert R., Lexchin J., and Moir H., “Financial Costs Associated With Monopolies on Biologic Medicines in Australia,” Australian Health Review 43, no. 1 (2019): 36–42. - PubMed
    1. Khoo T., Sidhu N., Marine F., et al., “Perceptions Towards Biologic and Biosimilar Therapy of Patients With Rheumatic and Gastroenterological Conditions,” BMC Rheumatology 6, no. 1 (2022): 79. - PMC - PubMed
    1. Council of Australian Therapeutic Advisory Groups , “Biologics and Biosimilars Best Practice: Guiding Principles for the Governance of Biologics and Their Biosimilars in Australian Hospitals,” 2021, https://catag.org.au/wp‐content/uploads/Guiding‐principles‐for‐the‐gover....
    1. Harvey R. D., “Science of Biosimilars,” Journal of Oncology Practice 13, no. 9_suppl (2017): 17s–23s. - PubMed

Substances

LinkOut - more resources